These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8216813)

  • 1. Enhanced liver MR: contrast agents and imaging strategy.
    Runge VM; Kirsch JE; Wells JW; Awh MH; Bittner DF; Woolfolk CE
    Crit Rev Diagn Imaging; 1993; 34(1-2):1-30. PubMed ID: 8216813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver MRI with contrast enhancement.
    Runge VM
    Crit Rev Diagn Imaging; 1997 Jun; 38(3):207-30. PubMed ID: 9226107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg).
    Giovagnoni A; Paci E
    Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):61-72. PubMed ID: 8673717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Focal liver lesions: whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose.
    Nural MS; Gokce E; Danaci M; Bayrak IK; Diren HB
    Eur J Radiol; 2008 Apr; 66(1):65-74. PubMed ID: 17555901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of Gd-BOPTA and Gd-DTPA in contrast-enhanced MR imaging of the liver].
    Zhang HM; Ouyang H; Zhou CW
    Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):111-5. PubMed ID: 16750014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hepatic and hepatocarcinoma magnetic resonance: comparison of the results obtained with paramagnetic (gadolinium) and superparamagnetic (iron oxide particles) contrast media].
    Castoldi MC; Fauda V; Scaramuzza D; Vergnaghi D
    Radiol Med; 2000 Sep; 100(3):160-7. PubMed ID: 11148882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual contrast enhanced magnetic resonance imaging of the liver with superparamagnetic iron oxide followed by gadolinium for lesion detection and characterization.
    Kubaska S; Sahani DV; Saini S; Hahn PF; Halpern E
    Clin Radiol; 2001 May; 56(5):410-5. PubMed ID: 11384141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detectability of small liver metastases with gadolinium BOPTA.
    Runge VM; Lee C; Williams NM
    Invest Radiol; 1997 Sep; 32(9):557-65. PubMed ID: 9291044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine.
    Bauner KU; Reiser MF; Huber AM
    Invest Radiol; 2009 Feb; 44(2):95-104. PubMed ID: 19077911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging.
    Schneider G; Altmeyer K; Kirchin MA; Seidel R; Grazioli L; Morana G; Saini S
    Invest Radiol; 2007 Feb; 42(2):105-15. PubMed ID: 17220728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
    Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
    Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mangafodipir trisodium injection (Mn-DPDP). A contrast agent for abdominal MR imaging.
    Rofsky NM; Earls JP
    Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):73-85. PubMed ID: 8673718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of [Gd(Bz-TTDA)]2- as a potential contrast agent in MR imaging of the hepatobiliary system: an animal study.
    Hsu JS; Jaw TS; Liu GC; Wang YM; Chen SH; Kuo YT; Jao JC; Li CW; Tsai KB
    J Magn Reson Imaging; 2004 Oct; 20(4):632-9. PubMed ID: 15390149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multinodular focal fatty infiltration of the liver: atypical imaging findings on delayed T1-weighted Gd-BOPTA-enhanced liver-specific MR images.
    Marin D; Iannaccone R; Catalano C; Passariello R
    J Magn Reson Imaging; 2006 Sep; 24(3):690-4. PubMed ID: 16878304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic abscesses. Magnetic resonance imaging findings using gadolinium-BOPTA.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1996 Dec; 31(12):781-8. PubMed ID: 8970881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of gadoxetate disodium as a contrast agent for mouse liver imaging: comparison with gadobenate dimeglumine.
    Kiryu S; Inoue Y; Watanabe M; Izawa K; Shimada M; Tojo A; Yoshikawa K; Ohtomo K
    Magn Reson Imaging; 2009 Jan; 27(1):101-7. PubMed ID: 18599243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MultiHance: help or hype?
    Bartolozzi C; Spinazzi A
    J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S151-9. PubMed ID: 10608411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gadobenate dimeglumine (Gd-DTPA) vs gadopentetate dimeglumine (Gd-BOPTA) for contrast-enhanced magnetic resonance angiography (MRA): improvement in intravascular signal intensity and contrast to noise ratio.
    Pediconi F; Fraioli F; Catalano C; Napoli A; Danti M; Francone M; Venditti F; Nardis P; Passariello R
    Radiol Med; 2003; 106(1-2):87-93. PubMed ID: 12951555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose gadobenate dimeglumine versus standard-dose gadopentate dimeglumine for delayed contrast-enhanced cardiac magnetic resonance imaging.
    Balci NC; Inan N; Anik Y; Erturk MS; Ural D; Demirci A
    Acad Radiol; 2006 Jul; 13(7):833-9. PubMed ID: 16777557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing lesions of the brain: intraindividual crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators.
    Essig M; Tartaro A; Tartaglione T; Pirovano G; Kirchin MA; Spinazzi A
    Acad Radiol; 2006 Jun; 13(6):744-51. PubMed ID: 16679277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.